Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
– U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – –  Growth Driven by Increase in Demand and Substantial Improvement in Net Price – –  Prescriptions Grew 28% During the Quarter; More Than
Toggle Summary Esperion to Participate in Upcoming Virtual Investor Conference
ANN ARBOR, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference. Event: BTIG Virtual Biotechnology Conference Date: August 9,
Toggle Summary Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webcast and conference
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., July 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on June 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 31 new employees (i) non-qualified stock options to purchase an aggregate of 88,692 shares of its common stock, all
Toggle Summary ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC,